Stock B1DX34 BECTON, DICKINSON AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Becton, Dickinson and Company Sao Paulo

Equities

B1DX34

BRB1DXBDR008

Delayed Sao Paulo
Other stock markets
 12:49:30 2024-06-25 EDT 		5-day change 1st Jan Change
254.1 BRL +0.42% Intraday chart for Becton, Dickinson and Company +8.91% +11.13%
12:45pm BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool CI
06-20 Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024 CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The group shows a rather high level of debt in proportion to its EBITDA.
  • With an expected P/E ratio at 32.82 and 29.08 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • With an enterprise value anticipated at 3.99 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company is not the most generous with respect to shareholders' compensation.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
+11.13% 67.59B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.16% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-2.39% 103B
C
CENCORA, INC. Stock Cencora, Inc.
+16.04% 46.93B
B-
DEXCOM, INC. Stock DexCom, Inc.
-11.10% 43.87B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.28% 41.2B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+17.63% 30.47B
B
TERUMO CORPORATION Stock Terumo Corporation
+13.59% 24.16B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.10% 23.57B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-11.08% 22.26B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BDX Stock
  4. B1DX34 Stock
  5. Ratings Becton, Dickinson and Company